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ABSTRACT 
 
MOLECULAR ANALYSIS OF MAMMALIAN NEU4  
SIALIDASE GENE PROMOTER 
 
 There are four different mammalian sialidases that have been described; 
lysosomal (Neu1), cytoplasmic (Neu2), plasma membrane (Neu3), 
lysosomal/mitochondrial (Neu4). The activity of sialidase Neu4 enzyme against sialic 
acid containing ganglioside GM2 has been demonstrated. Biological role of sialidase 
Neu4 enzyme has been shown by the transfection of  neuroglia cells from a Tay-Sachs 
patient with a Neu4-expressing plasmid showed clearance of accumulated ganglioside 
GM2. It has been also shown that sialidase Neu4 enzyme is responsible for degradation 
reactions of another  ganglioside such as GD1a in brains of Neu4
-/-
 mice. Aim of our 
study is to identify minimal promoter region of human Neu4 gene and demonstrate 
binding of transcription factors to this region. 
In our study, we used bioinformatic approaches to predict the sequence motifs 
where several specific transcription factors bind using TESS (Transcription Element 
Seach System) tool. We amplified seven different DNA fragments from human Neu4 
promoter region, cloned into luciferase expression vector and performed reporter assay. 
We also performed electrophoretic mobility shift assay to demonstrate binding of 
transcription factors to candidate promoter region. 
We demonstrated that 187 bp upstream of Neu4 gene is minimal promoter 
region to control transcription from Neu4 gene. Electrophoretic mobility shift assay 
showed that 187 bp upstream region recruits several transcription factors. 
Our results demonstrated the minimal promoter region revealing several putative 
transcription factors such as Sp-1 and c-myc which might be responsible mainly for 
regulation of Neu4 gene transcription. The data we obtained might be useful to discover 
small molecules which can control Neu4 gene expression. High expression of Neu4 
gene might be controlled using drugs or small molecules and the accumulated GM2 
ganglioside in lysosomes of Tay-Sachs patients can be reduced. 
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ÖZET 
 
MEMELİ NEU4 SİALİDAZ GEN PROMOTÖRÜNÜN 
 MOLEKÜLER ANALİZİ 
 
Memelilerde tanımlanmış dört farklı sialidaz enzimi bulunmaktadır. Bunlar; 
lizozomal (Neu1), sitoplazmik (Neu2), plazma membran (Neu3), 
lizozomal/mitokondrial (Neu4) sialidaz olarak sınıflandırılmıştır. Sialidaz Neu4 
enziminin, sialik asit içeren GM2 gangliozidine karşı olan aktivitesi gösterilmiştir. 
Sialidaz Neu4 enziminin biyolojik rolü Tay-Sachs hastasından alınan nöroglia 
hücrelerinin Neu4 ifade eden plazmid ile transfekte edilmesi sonucunda biriken GM2 
gangliozidlerin yıkıma uğraması ile gösterilmiştir. Bunun yanı sıra Neu4-/- fare 
beyinlerinde sialidaz Neu4 enziminin GD1a gangliozidinin yıkımından sorumlu olduguda 
gösterilmiştir.  
Çalışmamızda sialidaz Neu4 geninin minimal promotör bölgesinin moleküler 
analizi ve transkripsiyon faktörlerinin bu bölgeye bağlanması araştırılmıştır.  
Araştırmamızda, TESS (Transcription Element Seach System) programı 
kullanılarak bazı spesifik transkripsiyon faktörünün bağlandığı sekans motifleri 
biyoinformatik yöntemlerle tahmin edilmiştir. Yedi farklı DNA fragmenti insan Neu4 
promotör bölgesinden amplifiye edilip lusiferaz ekspresyon vektörüne klonlanarak 
lüminometrik ölçüm yapılmıştır. Transkripsiyon faktörlerinin muhtemel promotör 
bölgesine bağlanmasını göstermek için DNA:protein ilişkisini gösteren EMSA 
(electrophoretic mobility shift assay) deneyi gerçekleştirilmiştir. 
Neu4 geninin 187 baz çifti önünde yer alan bölgenin minimal promotör bölgesi 
olduğu gösterilmiştir. Transkripsiyon faktörlerinin 187 baz çiftlik bölgeye bağlandıkları 
kanıtlanmıştır.  
Minimal promotör bölge aydınlatılıp Neu4 geninin transkripsiyonunun  
regülasyonundan sorumlu olabilecek c-myc ve Sp-1 gibi transkripsiyon faktörleri 
belirlenmiştir. Elde edilen veriler gelecekte Neu4 geninin kontrolünü sağlayan küçük 
moleküllerin sentezlenmesinde rol oynayabilecektir. Neu4 geninin küçük moleküllerle 
veya ilaçlar ile ifadesinin artırılması Tay-Sachs hastalarının lizozomlarında biriken GM2 
gangliozidinin yıkımı sağlanabilecektir. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1. Neuraminidases 
 
Neuraminidases (EC 3.2.1.18), also known as sialidases, are glycohydrolytic 
enzymes that are responsible for removing sialic acid residues from sialylated 
glycoproteins, glycolipids and oligosaccharides (Magesh, Miyagi et al. 2006; Miyagi 
2008; Seyrantepe et al. 2004). Neuraminidases cause a conformational change in 
glycoconjugate structure by removing the sialic acid groups and this conformational 
change induce metabolic processes via recognition of these molecules (Miyagi 2008). It 
has been shown that neuraminidases are expressed in all cell types and tissues and 
involved in metabolic processes like cell proliferation, adhesion, differentiation, 
catabolism of glycolipids and glycoproteins, membrane fusion and fluidity (Saito and 
Yu, 1995; Bonten 2000). Neuraminidases have a wide distribution in nature among 
viruses, bacteria, protozoa and vertebrates (Saito and Yu 1995).  In humans, four types 
of neuraminidases have been identified and characterized according to their subcellular 
distribution, substrate specificity and stability (Magesh and Miyagi et al. 2006; Bonten 
2000).These neuraminidases are lysosomal Neu1 (Bonten 1996), cytosolic Neu2 (Monti 
1999), plasma membrane Neu3 (Monti et al. 2000) and lysosomal or mitochondrial 
membrane Neu4 (Monti et al. 2004). Although neuraminidases differ in substrate 
specificity, all human neuraminidases contain conserved active sites, the F/YRIV/P 
motif, in the N-terminal part and the Asp boxes (Roggentin et al. 1993).  
 
1.1.1. Neuraminidase 1 
 
Neu1 is expressed from the gene Neu1 which is located on human chromosome 
 6p21.3 (Bonten et al. 1996) and it has 6 exons spaning approximately 3.5 kb of 
genomic DNA (Milner et al. 1997). Vesicular transport system which is responsible for 
trafficking of molecules between different membrane-enclosed compartments in a cell 
2 
 
targets Neu1 to the endosomal-lysosomal system to be an integral membrane protein 
(Lukong et al. 2001). Subcellular locations of Neu1 can be listed as lysosomal 
membrane, peripheral membrane, lysosome lumen, cell membrane (Lukong and 
Seyrantepe et al. 2001). It is found in all vertebrate cells and tissue types like brain, 
kidney, liver, testis (Saito et al. 1995). It is mostly expressed in pancreas but weakly 
expressed in brain (Uniprot, 2011). Neu 1 is associated with -galactosidase and 
Cathepsin A in lysosomes and loss of this multienzyme complex causes reduction in 
Neu1 activity (Pshezhetsky et al. 1997). Neu1 is responsible for catalyzing the removal 
of sialic acid from glycoproteins and glycolipids hydrolysing of alpha-(23), alpha-
(26), alpha-(28) glycosidic linkages of terminal sialic acid residues. It has a narrow 
substrate specificity against oligosaccharides, glycopeptides and artificial substrates like 
4MU-Neu5Ac (4-methylumbelliferyl-N-acetylneuraminic acid) (Pshezhetsky et al. 
2001). Another important role of Neu1 is cellular immune response during monocyte 
differentiation by relocalizing from lysosomes to cell surface (Liang and Seyrantepe et 
al. 2006). Defects in Neu1 gene causes a neurodegenerative disorder called sialidosis 
which is an autosomal recessive lysosomal storage disease. Neu1 deficiency cause 
accumulation of sialylated oligosaccharides in the lysosome (Thomas et al. 2001). 
Sialidosis has two types; Sialidosis type I (the mild and late onset form) which shows 
gait abnormalities, progressive impaired vision, bilateral macular cherry-red spots and 
myoclonus syndrome (Durand et al. 1977; Rapin et al. 1978; O’Brien 1979) and 
Sialidosis type II (severe, early-onset form) which shows dysostosis multiplex, short 
stature, developmental delay, mental retardation and hepatosplenomegaly (Kelly and 
Graetz 1977; Winter et al. 1980). The confirmation of the diagnosis is performed by 
screening of the urine for sialyloligosaccharides (Uniprot, 2011) and patients can also 
be diagnosed biochemically by measuring lysosomal enzyme activities in cultured skin 
fibroblasts or amniocytes (Suzuki 1987). 
 
1.1.2. Neuraminidase 2 
 
Neu2 is expressed from the gene Neu2 which localizes on human chromosome 
2q37. It is located in cytoplasm and mostly expressed in skeletal muscle, fetal liver and 
embryonic carcinoma cell line NT2D1 (Uniprot, 2011). Neu2 hydrolyzes alpha-(23), 
alpha-(26), alpha-(28) glycosidic linkages of terminal sialic acid residues in 
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oligosaccharides, glycoproteins, glycolipids at approximatly neutral pH in contrast to 
lysosomal Neu1 sialidase (Miyagi et al. 1985; Tringali et al. 2004). Role of Neu2 in 
mammals is suggested in myotube formation (Sato 1996). The mechanism for myotube 
differentiation is claimed by decreasing GM3 ganglioside associated with the 
cytoskeleton leading to the alteration of cytoskeletal functions (Akita 1997; Sato 1997; 
Fanzani 2003). However, the exact function of Neu2 in cells and tissues is obscure and 
there is no identified genetic disorder associated with the deficiency of Neu2. 
 
1.1.3. Neuraminidase 3 
 
Neu3 is expressed from the gene Neu3 which is located on human chromosome 
11q13.5 (Wada et al. 1999). It plays role in the caveolae microdomains of plasma 
membranes (Wada et al. 1999; Wang et al. 2002). It has a high expression levels in 
skeletal muscle, testis, adrenal gland and thymus and low expression levels in  kidney, 
placenta, brain and lung (Wada et al. 1999). Neu3 is responsible for modulating 
oligosaccharide chains of gangliosides on lipid bilayer during transformation, 
differentiation and formation of cell interactions (Kopitz 1996; Kopitz 1998), being 
active against gangliosides that play role in signal transduction (Schneider-Jakob 1991). 
It has been shown that up-regulation of Neu3 is essential for cancer cell survival. 
However study with siRNA implicate that Neu3 is important player against cancer 
progression. Neu3 siRNA could be therapeutic agent providing apoptosis of cancer cells 
(Miyagi 2008).  
 
1.1.4. Neuraminidase 4 
 
Sialidase Neu4 enzyme is expressed from the gene Neu4 that maps in the 
telomeric region of the long arm of human chromosome 2 (2q37). Neu4 gene was 
discovered as a result of sequence database search that revealed homology to the human 
cytosolic sialidase Neu2 gene. Entire Neu4 gene is 6663 bp located in the position 
239447224 – 239453886 of chromosome 2q37.3 and has four exons. Sialidase Neu4 
enzyme has the highest expression level in liver and it is also ubiquitously expressed in 
all CNS (central nervous system) districts, colon, small intestine, kidney, heart, skeletal 
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muscle and placenta (Monti et al. 2004) and its expression is decreased during 
monocyte to macrophage differentiation (Stamatos et al. 2005). Sialidase Neu4 enzyme 
has two major isoforms; short form containing 484 amino acids with a molecular weight 
of 51.57 kDa (Monti et al. 2004) and long form containing 496 amino acids (Bigi et al. 
2009) and additionally 18 transcripts related to sialidase Neu4 enzyme has been listed as 
in Ensemble database. It has a F/YRVP sequence motif and two classical Asp blocks. 
Sialidase Neu4 enzyme has been firstly characterized as a member of lysosomes  and 
targeting of sialidase Neu4 enzyme to lysosomes by the mannose 6-phospate receptor 
has also been shown in literature (Monti et al. 2004). It has also been shown that 
sialidase Neu4 enzyme localizes in lysosomal lumen as a soluable hydrolase 
(Seyrantepe et al. 2004). In contradiction to these knowledge, it has been suggested that 
sialidase Neu4 enzyme long form localizes in mitochondria and sialidase Neu4 enzyme 
short form is associated with the endoplasmic reticulum (Bigi et al. 2009). Sialidase 
Neu4 enzyme has a broad substrate specificity almost equally against glycoproteins 
(mucin), oligosaccharides (sialyllactose) and sialylated glycolipids (mixed bovine 
gangliosides). It shows sialidase activity on synthetic substrates  2'-(4-
methylumbelliferyl)-alpha-D-N-acetylneuraminic acid (4-MU-NANA or 4MU-NeuAc) 
at acidic pH 3.2 (Monti et al. 2004). An additional function of sialidase Neu4 enzyme 
can be explained as lysosomal catabolism of sialylated glycoconjugates with a 
supporting evidence showing degradation of storage materials from lysosomes of 
sialidosis and galactosialidosis patients. Overexpressed sialidase Neu4 enzyme activity 
in sialidosis fibroblasts has been shown with the clearance of accumulated substrates 
and normal morphological phenotype of the lysosomal compartment. In addition to this 
data, complete elimination of storage materials in 55% of sialidosis and 25% of 
galactosialidosis cells was achived by 3–5% of Neu4-expressing cells indicating the 
therapeutical potential of sialidase Neu4 enzyme in sialidosis and galactosialidosis for 
enzyme replacement therapy. In vivo studies reveal that Neu4-/- mice show vacuolization 
and lysosomal storage in lung and spleen cells. Neu4-/- mice also have increased level of 
GD1a ganglioside and decreased level of GM1 ganglioside in brains as a supporting 
evidence of sialidase Neu4 enzyme desialylation activity against brain gangliosides 
(Seyrantepe et al. 2004). It has been shown that Neu4 is downregulated in human colon 
cancer cells and overexpression of Neu4 in cultured cells accelerates apoptosis and 
decreases invasiveness and motility (Miyagi 2008). 
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1.2 .    Lysosomes 
 
Lysosomes are digestive organelles in cells. Lysosomes are membrane-bound 
compartments that contain more than 50 acid hydrolases processing catabolism 
reactions of the cell at an acidic pH of 4.6-5 (Nilsson et al. 2003). Function of 
lysosomes is basicly degradation of macromolecules like proteins, polysaccharides, 
nucleic acids, glycoconjugates and phospholipids. These substances are transported to 
lysosomes via endocytosis, phagocytosis, autophagy or direct transport. Degraded 
products can be released from lysosomes via diffusion or transport systems and after 
their release, they can be utilized to build new macromolecules or they can be used to 
produce metabolic energy (Suzuki 1994). Lysosomes are classified as the primary 
lysosome, the secondary lysosome and the residual body according to their 
physiological functions. The primary lysosome is a membrane-bound compartment 
containing hydrolytic enzymes like phosphatase, glucuronidase, sulfatase, ribonuclease, 
and collagenase that were synthesized in rough endoplasmic reticulum. The secondary 
lysosome is the fusion of the primary lysosomes with membrane-bound vacuoles 
containing materials for degradation. Residual bodies contain undegradable or slowly 
degradable materials (Zhang et al. 2009). The transport of lysosomal enzymes and 
membrane protein to lysosomes is achieved via  trans Golgi network. Transport vesicles 
that bud from trans Golgi network deliver them to late endosomes. Lysosomal enzymes 
are recognized with their marker called mannose-6-phosphate(M6P) groups that 
attached to N-linked oligosaccharides. M6P Receptor Proteins recognize these M6P 
groups and provide package of hydrolases in to clathrin-coated vesicles which releases 
from trans Golgi network and deliver materials inside to a late endosome (Alberts, 
Johnson and Lewis et al. 2002). Besides hydrolases, proteases called cathepsins are 
present in lysosome. Cathepsins are also classified as three groups according to their 
amino acid content in active sites; cysteine cathepsins, aspartyl cathepsins and serine 
cathepsins (Zhang et al. 2009). Cathepsins are responsible for protein degradation, 
antigen presentation, bone resorption, and hormone processing (Turk et al. 2000). Some 
cathepsins like Cathepsin B and Cathepsin L are very important for maturation and 
integrity of the post-natal central nervous system (CNS) as a result of the data obtained 
from cathepsin B-/- L-/- mice showed brain atrophy (Felbor et al. 2002). 
Glycosphingolipids are also digested in lysosomes. They contain a hydrophobic 
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ceramide moiety and an extracytoplasmic oligosaccharide chain. They are classified 
into two groups, first one is neutral glycosphingolipids which contain monoglycosyl-
/oligoglycosylsphingoids and monoglycosyl-/oligoglycosylceramides, second one is 
acidic glycosphingolipids which contain sialosylglycosylsphingolipids(gangliosides), 
sulfatides, glycuronoglycosphingolipids, phospho- and phosphonoglycosphingolipids 
(National Library of Medicine, 2011). They are distributed in nature from bacteria’s cell 
membrane to man’s cell membrane and are the major glycans found in vertebrate brain. 
 
1.3 .   Lysosomal Storage Disorders 
 
Lysosomal Storage Disorders (LSDs) are a group of nearly 50 rare diseases 
characterized as accumulation of waste materials due to deficiency of some enzymes, 
activators, transporters resulting large lysosomes in cells. LSDs have a wide spectrum 
of clinical phenotypes in accordance with the age of onset, severity of symptoms and 
central nervous system manifestation. The type of accumulated material and its tissue 
distribution, genetic backgrounds and environmental factors determine the severity of a 
lysosomal storage disorder. LSDs are inherited autosomal recessively but Fabry disease 
and Hunter syndrome are inherited X-linked recessively. Patients with this disease are 
born healty but sympthoms become visible progressively. Pathophysiology of LSDs 
include developmental delay, movement disorders, seizures, dementia, deafness and 
blindness. In addition some LSDs show hepatomegaly, splenomegaly and cardiac 
problems. The prevelance of LSDs are suggested as 1/8000 (Berg 2005). LSDs are 
classified as i) defects in glycan degradation, ii) defects in protein degradation, iii) 
defects in lysosomal transporters, iv) defects in lysosomal trafficking and v) defects in 
lipid degradation in five groups according to their causes as shown in Table 1.1. In the 
group of defects in lipid degradation, there are such diseases like Fabry disease, Farber 
disease etc. and one of these disorders is Tay-Sach Disease. 
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1.4 .   Tay-Sachs Disease 
 
Tay-Sachs disease is one of the sphingolipid degradation disorder and 
characterized as accumulation of GM2 ganglioside due to the deficiency of beta-
hexosaminidase A enzyme. Beta-hexosaminidases are responsible for degrading amino-
hexose moieties containing beta-glycosidic bonds from terminal part of glycoproteins, 
proteoglycan and glycolipids (Mark et al. 2003).  This disease causes neurodegeneration 
including developmental arrest, progressive neurological deficits and a shortened life 
span (Kolodny 1966). This group of condition contains two main disorders called Tay-
Sachs disease and Sandhoff disease (Jeyakumar 2002). Tay-Sachs disease is an 
autosomal recessive disorder caused by the defects in alpha-subunit of the beta- 
hexosaminidase A that has 2 different subunits ( one alpha and two beta) (Okada and 
O’Brien, 1969) resulting GM2 ganglioside accumulation in neuronal cells (Gravel et al. 
1995).  
 
Table 1.1. Lysosomal Storage Disorders 
 
Disorder Primary deficiency 
(secondary deficiency) 
Substrate 
Disorders of sphingolipid degradation 
Fabry disease 
Farber disease 
Gaucher disease 
GM1 gangliosidosis 
GM2 gangliosidosis 
     Tay-Sachs disease 
     Activator  deficiency 
     Sandhoff disease   
Krabbe disease 
Metachromatic leukodystrophy 
      Enzyme-deficient form 
      Activator-deficient form 
Mucolipidosis IV 
Multiple sulphate deficiency 
Niemann-Pick disease 
Schindler disease 
 
Alpha-galactosidase 
Ceramidase 
Glucocerebrosidase 
beta-galactosidase 
 
beta-hexosaminidase A 
GM2 activator 
beta-hexosaminidase A and B 
Galactosylceramidase 
Arylsulfatase A 
Saposin 
(Ganglioside sialidase) 
(Deficiency of all sulfatases) 
Sphingomyelinase 
Alpha-N-acetylgalactosaminidase 
 
Gal-Gal-Glu-ceramide 
Ceramide 
Glucosylceramide 
GMI ganglioside 
 
GM2 ganglioside 
GM2  ganglioside 
GM2  ganglioside 
Galactosylceramide 
 
Galactosylsulfatide 
Galactosylsulfatide 
 
(sulfatase substrates) 
Sphingomyelin 
a-galNAc glycolipids 
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GM2 ganglioside is catabolized with the combination of beta- hexosaminidase A 
and GM2 activator that makes substrate accessible and soluble for beta- hexosaminidase 
A (Meier et al. 1991). The in vivo studies reveal various substrates accumulated in GM2 
gangliosidosis (Sandhoff et al. 1989; Sandhoff 1991) as shown in Table 1.2.     
Several variants of Tay-Sachs disease can be listed as beta1 variant, pseudo-
deficiency, infantile, juveline and adult Tay-Sachs disease. Infantile Tay–Sachs Disease 
is the most common variant of the disease. Patients with infantile Tay–Sachs disease 
have zero activity of HexA and are affected by the disease in the first few months of 
their life showing neurodevelopmental delays and deficits like being less responsiveness 
to the environment, low facial expression, seizures, blindness, disability of crawling and 
standing, cherry-red spot in both optic fundi causing early death of the patient (Sachs 
1887; Gravel et al. 1995).  
 
Table 1.2. Storage of GSL in the GM2 gangliosidosis  
(Source: Mahuran 1999) 
 
 GM2 
(nmol/g) 
GD2 
(nmol/g) 
GD1a 
(nmol/g) 
GalNac- 
GD1a 
(nmol/g) 
GA2 
(nmol/g) 
Gb4b 
 (nmol/g) 
Control 20 40 500 2 0 180 
Tay-Sachs 10000 80 400 30 1000 400 
AB-variant 18000 90 200 2 4000 200 
Sandhoff 9000 100 300 10 5000 2000 
 
 
The autopsies of the patients provide knowledge about the disease’s pathology 
having severe cerebral and cerebellar atrophy, neuronal degeneration (Johnson et al. 
1980), ballooned neurons and neuronal loss (Moriwaki et al. 1977). Juvenile Tay–Sachs 
Disease appears between the ages of 3 - 5 following with ataxia, deterioration of 
activities, worsening motor functions and spasticity (Brett et al. 1973; Specola et al. 
1990) generally causing death between the ages of 15-20 (Nardocci et al. 1992). Adult 
Tay–Sachs Disease is late onset form of the disease and appears at the age of nearly 18 
with slowly progressing neurodegeneration (Neudorfer et al. 2005) with ataxia, gait 
disturbances, weakness, proximal muscle wasting, cramps, and fasciculations (Harding, 
Young, and Schon 1987; Federico 1987) and these patients do not present cherry-red 
spots. Beta-1 variant of the disease include a mutant HexA similar to wild-type HexA, 
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caused by the mutation in nucleotide 533 (GA substitution) resulting an amino acid 
change (R178H) in the protein (Ohno and Suzuki, 1988) and present a phenotype 
including megalencephaly and macular cherry-rod spot (Grosso et al. 2003). Patients 
with pseudo deficiency show low HexA activity in vitro but no GM2 ganglioside 
accumulation or disease symptoms (Triggs-Raine et al. 1992). AB-variant of GM2 
gangliosidoses is caused by the mutations in the GM2A gene that produces GM2 
activator which is responsible for proper function of beta-hexosaminidase. Sympthoms 
of this disease are inability of sitting, crawling, seizures, vision and hearing loss, mental 
retardation, and paralysis (OMIM 2011; Mahuran 1999). Sandhoff disease is also a lipid 
storage disorder caused by deficiency of functional beta-hexosaminidase A and B 
(Sandhoff et al. 1968). Major stored materials are GM2 ganglioside and oligosaccharides 
(Sandhoff et al. 1989). The main reason of deficiency is mutations in HEXB gene 
(Gomez-Lira et al. 1995). Clinical features are very similar to Tay-Sachs disease 
including blindness, progressive mental and motor deterioration, cherry red spots and 
macrocephaly. Patients die by the age of 3 years (OMIM, 2011). 
The mouse models of Tay-Sachs disease has been generated by the targeted 
disruption of the HexA gene. Analysis of these knock-out mice revealed that although 
GM2 ganglioside accumulated in the brain, mice did not present any kind of human Tay-
Sachs phenotype like behavioural or motor abnormalities even at the age of 1 year. 
Explaination of this situation is that HexA-/- mice possess a lysosomal neuraminidase 
sufficiently and they can convert GM2 to GA2 ganglioside and lactocyl ceramide by 
HexB isoenzyme as shown in the Figure 1.1 (Cohen-Tannoudji et al. 1995; Phaneuf 
1996; Sango 1995). 
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Figure 1.1.  Possible by-pass mechanism of sialidase Neu4 enzyme shown with red 
arrows. GLB, beta-galactosidase; GM2AP, GM2 activator protein; GBA, 
acid beta-glucosidase; SAPC, sapocin C (Adapted from: Seyrantepe et al. 
2008)   
 
Mice can convert GM2 to GA2 with their neuraminidase whereas human may not 
because of low abundancy of neuraminidase. Targeted disruption of HexA in mice 
prevented conversion of GM2 to GM3 ganglioside like in Tay-Sachs patients. It has been 
shown that mice fibroblasts convert GM2 to GA2 which is a asialo-GM2 produced by a 
sialidase, instead of converting to GM3 (Phaneuf 1996; Sango 1995). This metabolic by-
pass prevent mice to present phenotype of Tay-Sachs disease. 
Mice double-deficient in HexA-/- and Neu4-/- have been generated and epileptic 
crisis, degenerating neurons, motor impairment like tremor, weakness, spasticity and 
additionally GM2 ganglioside accumulation have been observed in contrast to single 
knock-out HexA-/- or Neu4-/- mice. This data reveals that due to sialidase Neu4 enzyme 
deficiency,  HexA-/- mice show a severe phenotype supporting the modifier role of 
sialidase Neu4 enzyme in the metabolic by-pass of Tay-Sachs disease mouse model. 
The increase in disease severity in double deficient mice indicate that sialidase Neu4 
enzyme is not the only responsible enzyme for by-pass mechanism. All these data 
suggest that sialidase Neu4 enzyme might be a potential therapeutic modifier by a 
pharmacologic induction through its upregulation with an agent in the future 
(Seyrantepe et al. 2010). 
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1.5 .   Transcriptional Machinery 
 
Healty development and maintenance of an organism needs correct spatial and 
temporal expression of its genes. This regulated expression is provided by the process 
of transcription. Transcription is the process of producing complementary RNA 
molecule using the DNA as a template (Narlikar and Ovcharenko 2009). Transcription 
begins with the binding of RNA Polymerase Complex to the DNA sequence called 
promoter in all organisms. RNA Polymerase Complex triggers transcription initiation 
followed by elongation of the transcript. Transcription is regulated in two different 
ways; the promoter level (cis-regulation) and the RNA Polymerase level (trans 
regulation). These regulatory mechanisms are different among prokaryotes and 
eukaryotes. 
Eukaryotic organisms have different types of tissues and cells. Proper function 
of these cells is maintained by the process called transcriptional regulation that includes 
correct expression of thousands of genes in the organism. This regulation can be 
achived by transcription factors that bind specifically to the DNA sequences called 
transcription factor binding sites. Generally different types of transcription factors 
function together providing the regulation of excess numbers of protein coding genes. 
The transcript of the desired gene is transcribed by RNA Polymerase II that recognize 
the transcription start site (TSS) with the existence of the general transcription factors 
(GTFs). A special DNA region called core promoter presents TSS and other binding 
sites for different subunits of GTFs to form a complex and provides binding of RNA 
Polymerase to this assembly to form transcription initiation complex (TIC). The 
eukaryotic transcription machinery can be classified into two groups; trans-acting 
elements that are DNA binding proteins and cis-acting elements that are specific DNA 
regions (Narlikar and Ovcharenko 2009).  
Trans-regulatory elements constitute transcription factors (TFs). Transcriptional 
factors contain two major domains; a DNA-binding domain and a transcription 
regulation domain (Mitchell 1989). The DNA binding domain is responsible for 
recognizing the specific DNA sequence and binding of the TFs to this sequence. The 
transcription regulation domains are responsible for binding transcriptional regulatory 
proteins to the TF to form functional complexes (Kummerfeld 2006). It is suggested 
that 10% of the gene products in human genome are candidate transcription factors, 
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nearly 1400 TFs (Vaquerizas 2009) and the number of candidate transcription factors 
might be related to the genome size and organism complexity proportionally (van 
Nimwegen 2003). Main functions of trans-regulatory elements are gene activation and 
gene repression (Narlikar and Ovcharenko 2009). Both mechanisms include DNA-
binding proteins and non-DNA binding proteins. Gene activation is mediated with 
binding of DNA-binding proteins (activators) to a region of 5-15 bp DNA sequence 
(Bulyk 2003). Activators can bind to the core promoter that places in proximal promoter 
region and 5’ untranslated region (UTR) and they can also bind to enhancer that place in 
distal promoter region resulting activation of transcription due to TIC attraction 
(Khoury 1983). Non-DNA binding proteins (co-activators) are responsible to combine 
GTFs and activators to trigger TIC formation (Narlikar et al. 2002). Gene repression 
also includes DNA-binding proteins (repressors) and non-DNA binding proteins (co-
repressors) as mentioned before. DNA-binding proteins (repressors) may inhibit 
transcription by competing with activator, interfering the activator’s activity due to 
close proximity, inhibiting TIC formation as a result of binding to silencers, causing 
lack of communication due to binding to insulators. Nucleosomes are also classified as 
repressors for their ability to prevent incorrect transcriptions (Kaplan 2003). Non-DNA-
binding proteins (co-repressors) that do not bind to DNA directly may inhibit 
transcription via protein-protein interactions through blocking the binding of activators 
and TIC to DNA by reorganization of the chromatin structure, forming useless activator 
complex to bind DNA or co-activator, inhibiting TIC directly. 
Transcription factors can not operate themselves. They co-operate with specific 
sequences of target genes (Madan 2003). These binding sites are called cis-regulatory 
elements and are classified according to their function or genomic location; promoters, 
enhancers, silencers and insulators as shown in Figure 1.2. Promoters are devided into 
two groups containing core promoter which is about 100 bp around the TSS (Carey et 
al. 2001) and proximal promoter which places a few base pair further from TSS 
(Maston 2006). Core promoter localizes the start of a gene and presents binding sites for 
GTFs and preinitiation complex (PIC). The core promoter elements are TATA box, an 
Initiator element (Inr), a Downstream Promoter Element (DPE), Downstream Core 
Element (DCE), a TFIIB-Recognition Element (BRE), and a Motif Ten Element (MTE) 
(Lim et al. 1990). 
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Figure 1.2. Mammalian regulatory elements  
(Source: Glenn et al. 2006) 
 
 TATA box presents binding site for TBP (TATA binding protein) which is a 
subunit of TFIID, BRE is specifically recognized by TFIID. DPE interacts with TAF6 
and TAF9, Inr interacts with TAF1 and TAF2, DCE interacts with TAF1 (Lee et al. 
2005, Smale 2003). It is suggested that there might be undiscovered promoter structures 
like ATG deserts due to the absence of these core promoter elements in quarter of all 
promoters (Lee et al. 2005). The proximal promoter localizes close to upstream of core 
promoter and presents binding sites for activators. Enhancers localizes a greater 
distance from TSS harbouring the binding sites of multiple activators. They can be 
found in upstream, downstream or within an intron sequence of the gene (Blackwood 
1998). There are two mechanisms related to enhancer activity, looping and DNA 
scanning. Looping theory includes binding of activators to enhancers enabling the loop-
out between enhancer and the core promoter bringing activators close to the promoter. 
According to this theory promoter ensure correct gene activation (Carey et al. 2001). 
DNA scanning mechanism includes movement of activators along the DNA until they 
reach the correct target promoter as a result of enhancer binding (Blackwood 1998). 
 Silencers are sequence specific elements repressing the transcription of a gene 
functioning independently from the promoter. There are also some silencers reported as 
position-dependent manner. Silencers can be included in enhancers or they can function 
as independent modules containing repressor binding sites (Ogbourne 1998). Insulators 
are responsible for preventing a gene being affected from the other gene that has a 
transcriptional activity by decreasing the activity of transcriptional regulatory elements 
inside the certain domains. They function in two different ways, by inhibiting the 
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enhancer/silencer and promoter interaction or by stopping the spread of repressive 
heterochromatin (Gaszner 2006). There are also additional regulatory elements in 
human genome, locus control regions (LCRs) and matrix attachment regions (MARs). 
Locus control regions (LCRs) are responsible for regulation of a cluster of genes in 
some specific cell types (Li et al. 2002). MARs are suggested to play a role in changes 
in chromatin structure for accessibility to transcription factors (Hart and Laemmli 
1998).  
 
1.6 .   Transcriptional Regulatory Elements and Human Diseases 
 
Cis-regulatory sequences are very important for healthy control of gene 
expression. Alteration in gene expression is an indicator of human disease susceptibility 
with a high heritable manner. Human genetic diseases caused by mutations in non-
coding regulatory sequences increase rapidly. 1459 regulatory mutations were 
connected to 700 genes causing human-inherited disorders and 1% and 2% of these 
mutations harbour in noncoding regions of the genome majoring proximal and distal 
promoter elements according to Human Gene Mutation Database. These mutations have 
very significant morphological, physiological and neurological consequences (Epstein 
2009) as listed in Table 1.3.  
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Table 1.3. Transcriotion regulatory elements and diseases 
(Source: Glenn et al. 2006) 
 
Regulatory 
Element 
Disease Mutation (bound factor) Affected 
Gene 
Core promoter 
-thalassemia TATA box, CACCC box, 
DCE 
-globin 
Proximal 
promoter 
Charcot-Marie-Tooth disease 
Hemophilia 
Progressive myoclonus 
Epilepsy 
 
-thalassemia 
-thalassemia 
215 bp upstream of TSS 
CCAAT box (C/EBP) 
Expansion  70 bp upstream of TSS 
 
CACCC box (EKLF) 
77 bp upstream of TSS (GATA-1) 
connexin-32 
factor IX 
cystatin B 
-globin 
-globin 
Enhancer 
X-linked deafness 
 
Microdeletions 900 kb upstream POU3F4 
Silencer 
Asthma and allergies 
 
509 bp upstream of TSS (YY1) TFG- 
Insulator 
Beckwith-Wiedemann 
syndrome 
 
CTCF binding site (CTCF) H19/Igf 
LCR 
 
-thalassemia 
-thalassemia 
62 kb deletion upstream of gene cluster 
 
30 kb deletion removing 5’ HS2–5 
-globin 
genes 
-globin 
genes 
 
 
It has also been shown that mutations in components of the transcriptional 
machinery are related to human diseases listed in Table 1.4. 
 
 
Table 1.4. Regulatory components and diseases  
(Source: Glenn et al. 2006) 
 
Component Disease Mutated Factor 
General transcription factors Xeroderma pigmentosum TFIIH 
Activators 
Congenital heart disease 
Down syndrome with acute  
Nkx2–5 
GATA-1 
Repressors X linked autoimmunity-allergic  FOXP3 
Coactivators Parkinson’s disease DJ-1 
Chromatin remodeling factors 
Retinal degeneration 
Rett syndrome 
-thalassemia myelodysplasia syndrome 
ataxin-7 
MeCP2 
ATRX 
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1.7 .   Genetic Reporter Systems 
 
Reporter genes have been preferred to investigate biological processes via their 
transcriptional regulation (Wood 1995). Reporter genes like -galactosidase (lacZ), 
firefly luciferase (luc), bacterial luciferase (luxCDABE) and green fluorescent protein 
(gfp) have been used for detection of molecular events like receptor activity, 
transcription factors, intracellular signaling, mRNA processing, protein folding and it is 
also used to understand if a gene had been taken up into a cell/organism or expressed. 
Mechanism of this method includes the attachment of the reporter gene to a regulatory 
sequence and insertion of this structure into a biological system then obtaining a signal 
via its own expression (Wood 1995). The mostly used three reporter systems are -
galactosidase, luciferases and fluorescent proteins. -galactosidase protein (-gal) 
converts lactose to galactose and glucose. This enzyme is also capable of degrading 
such substrates like chromogens o-nitrophenol -D-galactopyranoside (ONPG), 5-
bromo-4-chloro-3-indolyl--D-galactopyranoside (X-gal), 3,4-cyclohexenoesculetin--
D-galactopyranoside (S-gal) (James et al. 1996), giving yellow, blue and black 
products, respectively. Green fluorescent protein is the most common fluorescent 
protein used in reseach and it is functional in both eukaryotes and prokaryotes. The 
advantages of using fluorescent proteins are wide spectrum of hosts, absence of cell 
lysis or substrate addition. Different colors of variants like blue, yellow and red are 
available commercially ( ClonTech Inc.). The disadvantage of this system can be 
explained that fluorescent proteins continue emitting fluorescence after host died and 
the fluorophore of the wild-type GFP protein should be renewed by biological processes 
(Heim et al. 1995; Katranidis 2009). Luciferases are the enzymes producing 
luminescence and are classified as eukaryotic or bacterial. Firefly luciferase (luc) is the 
most commonly preferred reporter gene (de Wet et al. 1987) having the benefits of high 
sensitivity, tight coupling of the Luc protein concentration with luminescence output, no 
requirement of post-translational modifications, immediate activity after translation (de 
Wet et al. 1985). Firefly luciferase (Photinus luciferin:oxygen 4- oxidoreductase, EC 
1.13.12.7) was isolated from Photinus pyralis. It is a 61kDa monomeric protein that 
functions without post-translational processing. This enzyme converts beetle luciferin 
into oxyluciferin giving a photon emission as an by product shown in the Figure 1.3 
(Wood et al. 1984; de Wet et al. 1985) and this light is detected with luminometers, 
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additionally it has an optimum pH of 7.8 (Steghens, Min and Bernengo 1998). 
Luciferases are generally preferred for transcriptional activity research (Fan and Wood 
2007) in cells transfected with a plasmid containing a luciferase gene as an reporter 
driven with a candidate promoter as shown in Figure 1.3. 
 
 
Figure 1.3. Catalytic reaction of luciferase 
(Adapted from: Promega technical manuel; Fan and Wood 2007) 
 
 The disadvantage of this system is need for costly substrate, luciferin for 
monitoring and measuring.  
 
1.8 .   Electrophoretic Mobility Shift Assay (EMSA) 
 
Regulation of many cellular processes like DNA replication, recombination, 
repair, transcription are maintained by interaction of proteins with DNA. EMSA is 
based on slow migration of DNA:protein complexes which is caused by protein binding 
than free DNA molecules that are run on native polyacrylamide gel or agarose gel 
electrophoresis (Hendrickson 1985; Revzin 1989). This retarded DNA:protein 
complexes are called as shifts. Crude nuclear or whole cell extracts rather than purified 
proteins can be used as a source of DNA binding proteins. EMSA can be used as 
qualitatively by identifying DNA binding proteins that are specific to a given sequence 
with mutagenesis or identifying specific sequences of a gene’s upstream region and as 
quantitatively by measuring thermodynamic and kinetic parameters of binding reactions 
(Fried et al. 1981; Garner et al. 1981; Fried et al. 1984; Fried 1989). Resolving ability is 
based on stability of DNA:protein complexes which is in fact unstable but maintained 
stabile with low ionic strenght of electrophoresis buffer during migration in the gel. 
Nucleic acids which can be a double-stranded DNA, RNA molecule used in EMSA can 
be labelled radioisotopes, fluorophores and biotin and these labels can be detected by 
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autoradiography, fluorescence imaging and chemiluminescent imaging, respectively 
(Rye et al. 1993; Forwood et al. 2006; Kang et al. 2005; Li et al. 2004). Binding of 
nonspecific proteins to the labeled target DNA is reduced by nonspecific competitor 
DNA which are repetitive polymers called as poly(dIdC) or poly(dAdT) that are 
responsible for adsorbtion of proteins that bind to any general DNA sequence to their 
nonspecific sites. Determining the specificity of DNA:protein binding is achieved with 
addition of 50, 100, 150 etc. excess of unlabelled DNA concentration for competition 
assays (Lane 1992).  
 
 
Figure 1.4. Electrophoretic mobility shift assay 
(Adapted from: Biochem.arizona , 2011) 
 
When an antibody which is specific to a transcription factor included in the 
binding reactions of DNA and proteins, antibody can bind specifically to the 
transcription factor that is bound to the DNA. This DNA:protein:antibody complex 
migrates more slowly than ‘shift’ and also free labelled DNA and called as supershift as 
shown in Figure 1.4  (Kristie 1986). 
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1.9.  The Aim of the Study 
 
The aim of the study is to identify promoter region of human sialidase Neu4 
gene which has not been studied yet. We also aimed to show specific interactions of 
transcription factors in the promoter region.  
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CHAPTER 2 
 
                MATERIALS AND METHODS 
 
2.1.    Bioinformatic Analysis of Promoter Region for Neu4 Gene and  
Primer Design   
 
3000 bp upstream region from Neu4 gene start codon (ATG) were considered to 
be a region containing the regulatory elements for Neu4 gene. The sequence of 3000 bp 
were obtained from NCBI (The National Center for Biotechnology Information). This 
sequence were input to TESS (Transcription Element Search System) for analysis and 
mapping of transcription binding sites in it. After obtaining the map of transcription 
binding sites, reverse and forward primers were designed  according to different motifs 
as shown in Table 2.1 for further regulation studies using PrimerDesign3 tool (version 
0.4.0, http://frodo.wi.mit.edu/primer3/).  
 
2.2.    Primers 
 
Primers were designed to obtain seven different DNA fragments between 187 bp 
and 3011 bp according to their transcription factor binding sites as shown in the Figure 
2.1. These primers also included restriction sites at their 5’ ends for cloning into 
reporter vectors during further assays. That’s why reverse primer which is shared for all 
forward primers during PCR contain a NheI restriction site (GCTAGC) and forward 
primers contain a KpnI restriction site (GGTACC) as shown below. 
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Table 2.1. Reverse and Forward primers 
 
Primers Sequence 
F1 5’- GGTACCCTCCTGGGTGCCCATCTG- 3’ 
F2 5’- GGTACCTCTCTGGAGCAGCAGACC- 3’ 
F3 5’- GGTACCGTGAATGGGACTGGCAGGAG- 3’ 
F4 5’- GGTACCGGGGGAAGCTTTCCTTAACC- 3’ 
F5 5’- GGTACCACACCCTGGCCAGACAGC- 3’ 
F6 5’- GGTACCCCTGTCCCTGAGCGGAAC- 3’ 
F7 5’- GGTACCCTCCGTGTCAGTGTGCATTC- 3’ 
Reverse primer 5’- GCTAGCGCTGCAGAGCTCATCATGG- 3’ 
 
 
 
 
 
Figure 2.1. Primers amplifying seven different DNA regions 
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2.3.     Plasmids 
 
 There are three different plasmids used in this study. These plasmids can be 
listed as pCR 2.1 TOPO TA cloning vector, pGL 4.12 Firefly vector and pGL 4.74 
Renilla vector shown in the Figure 2.2 - 2.3 - 2.4 .   
 
 
Figure 2.2. pCR 2.1 TOPO vector(Invitrogen) 
 
 
 
                                    
 
    Figure 2.3. pGL 4.12 vector (Promega)            Figure 2.4. pGL 4.74 vector (Promega) 
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2.4.     Commercial Kits  
 
Table 2.2. Commercial kits 
 
Kits  Supplier Company 
Wizard® Genomic DNA Purification Kit Promega,  
i-Taq DNA Polymerase Intron Biotechnology 
Genejet Gel Extraction Kit Fermentas 
TOPO TA Cloning Kit Invitrogen 
GeneJET™ Plasmid Miniprep Kit Fermentas 
PureLink™ Plasmid DNA Purification Kits Invitrogen 
GeneJET™ PCR Purification Kit Fermentas 
TurboFect™ in vitro Transfection Reagent Fermentas 
Dual-Luciferase® Reporter Assay System Promega 
NE-PER® Nuclear and Cytoplasmic Extraction Reagents Thermo Scientific 
Pierce® BCA Protein Assay Kit Thermo Scientific 
Biotin 3' End DNA Labeling Kit Thermo Scientific 
LightShift® Chemiluminescent EMSA Kit Thermo Scientific 
 
 
2.5.    DNA Isolation, PCR Amplification of Seven Different Fragments    
 
Human DNA were isolated from blood with Wizard® Genomic DNA 
Purification Kit (Promega, A1125) according to manufacturer’s instructions. This DNA 
was used in Polymerase Chain Reaction (PCR) with i-Taq DNA Polymerase (Intron 
Biotechnology, 25022). Seven different fragments were amplified with specific primers 
designed before in the mixtures and conditions as shown in Table 2.3 and Table 2.4, 
respectively.  
After DNA fragments amplified with PCR, they were run in 1% agarose gel. 
Fragments were purified using Genejet Gel Extraction Kit (Fermentas, K0513) from 1% 
agarose gel. 
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Table 2.3. PCR mixture 
 
Components Volume (l) 
dH2O 40 
10X Buffer 2 
DMSO 2.5 
dNTPs (2,5 mM each) 2 
Reverse Primer (100 pmol) 1 
Forward Primer (100 pmol) 1 
Template DNA (70 ng/l) 1 
i-Taq DNA Polymerase(5 U/l) 0.5 
Total Volume 50 
 
 
Table 2.4. PCR conditions 
 
Cycle 
Number 
Cycle Temperature(oC) Duration 
1 Initial Denaturation 94 2 minutes 
Denaturation 94 20 – 30 seconds 
Annealing 58 – 65 30 seconds – 1 minute 30 
Elongation 68 45 seconds– 2 minutes 
1 Final Elongation 72 5 – 10 minutes 
 
 
 
2.6.    TA Cloning and Confirmation with Restriction Enzyme 
Digestion    
 
Purified DNA fragments were cloned with TOPO TA Cloning Kit (Invitrogen, 
K4520-01) according to manufacturer’s instructions. One Shot® MAX Efficiency® 
DH5  -T1R Chemically Competent E. coli cells (Invitrogen, 12297-016) were used for 
bacterial transformation. White colonies were selected by blue-white screening. These 
selected colonies were inoculated into LB-broth medium containing 100 g/ml 
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kanamycin and incubated at 37 oC in a shaker incubator for overnight. Plasmids were 
purified using GeneJET™ Plasmid Miniprep Kit (Fermentas, K0502). Purified plasmids 
were digested with EcoRI restriction enzyme at 37 oC for 2 hours for confirmation of 
the TA cloning as shown in Table 2.5. 
 
Table 2.5. Digestion Mixture 
 
Component Volume (l) 
dH2O 15.25 
10X Buffer 2.0 
Plasmid (0.5 g) 2.5 
EcoRI (10 u/l) 0.25 
Total volume 20 
 
 
All digestion mixtures were run on 1% agarose gel for detection of confirmation. 
 
2.7.    Sequence Analysis of the Cloned Fragments and BLAST Search    
 
Cloned TOPO plasmids containing seven different fragments were sequenced at 
Izmir Institute of Technology, Biotechnology and Bioengineering Research and 
Application Center as a service provider by different fluorescent dye labelled 
dideoxynucleotide chain terminating method. Cloned TOPO vectors were sequenced 
with both M13 primer and T7 primer. The sequences obtained from the sequencer were 
analysed using BLAST (Basic Local Alignment Search Tool).  
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2.8. Propagation and Confirmation of Firefly and Renilla Plasmids    
 
              pGL 4.12 (Firefly) and pGL 4.74 (Renilla) plasmids were kindly provided from 
Prof. Dr. Bünyamin Akgül from Izmir Institute of Technology, Department of 
Molecular Biology and Genetics. These plasmids were propagated as midipreps with 
PureLink™ Plasmid DNA Purification Kit (Midiprep, Invitrogen, K2100-04). These 
plasmids were confirmed using PstI and AccI at 37 oC for 16 hours for pGL4.12 and 
AlwNI and BalI at 37 oC for 16 hours for pGL 4.74. Digestion mixtures were loaded on 
1% agarose gel and run. 
 
2.9.    Cloning of the Fragments into pGL 4.12 Firefly Vector    
 
Cloning efficiency is highly related to formation of sticky ends at the ends of 
vector and inserts. Enzyme units and buffer selection were determined as a 
recommendation of Fermentas Double Digestion Tool (http://www. fermentas.com 
/en/tools/doubledigest). We double digested pGL4.12 with NheI and KpnI separately. 
KpnI was used for first digestion for 1 hour at 37 oC in KpnI buffer and then KpnI was 
denatured at 80 oC for 20 minutes. NheI was added into the digestion mixture and 
incubated at 37 oC for 1 hour more.   
At the end of the incubations, digestion mixture was purified using GeneJET™ 
PCR Purification Kit (Fermentas, K0701) and its concentration was determined as 0.5  
ng/l. Separately digested pGL 4.12 was used for cloning of all seven fragments. TOPO 
vectors including our DNA inserts were digested with KpnI and NheI at 37 oC for 2 
hours at the same time. At the end of the digestions, all mixtures were run on 0.8 % 
agarose gel and inserts were extracted with Genejet Gel Extraction Kit ( Fermentas, 
K0513) and their concentration were measured with nanodrop (NanoDrop 
Technologies, Inc. ND-1000 spectrophotometer). Purified inserts were used in ligation 
with double digested pGL 4.12 with T4 DNA Ligase (Invitrogen, 15224-017) according 
to manufacturer’s instructions. 
After ligation, 2 microliters of each ligation mixture were transformed into One 
Shot® MAX Efficiency® DH5  -T1R Chemically Competent E. coli cells (Invitrogen, 
12297-016) according to manufacturer’s intructions and bacterial cells were plated on 
100 g/ml Ampcillin LB-agar plates following 16 hours incubation at 37 oC. All 
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transformations produced colonies on the plates and they were inoculated into 100 
g/ml Ampcillin LB-broth medium for 16 hours at 37 oC. After overnight incubation, 
cloned pGL 4.12 vectors were isolated from bacterial cultures with GeneJET™ Plasmid 
Miniprep Kit (Fermentas, K0502). These recombinant plasmids were confirmed by 
double digestion with NheI and KpnI at 37 oC for 2 hours. Double digestions showed 
that all seven fragments were cloned into pGL 4.12 firefly vector. Due to correct 
cloning of fragments as a result of double digestions, large scale plasmid production 
was performed by inoculating miniprep bacterial cultures into nearly 50 ml LB-broth 
containing 100 g/ml Ampicillin incubating at 37 oC for 16 hours and isolating with 
PureLink™ Plasmid DNA Purification Kit (Invitrogen, Midiprep K2100-04).     
 
2.10.  Transfection of Luciferase Vectors into HeLa Cells and   
Optimization of Dual Luciferase Reporter (DLR) Assay System  
 
HeLa cells were maintained in T25 tissue culture flasks in their growth medium 
called DMEM medium that contains 20% FBS, 1% Penicillin, 2mM L-Glutamine. 
These cells were transferred into 96-well plates for transfection assays. Fermentas 
Turbofect in vitro transfection reagent was used for all of the transfections according to 
manufacturer’s instructions. For optimization of DLR assay, different ratios of pGL 
4.12 and pGL 4.74 vectors and different incubation times were investigated. Ratios of 
10:1 (pGL 4.12 : pGL 4.74) ,  respectively and 30:1(pGL 4.12 : pGL 4.74) , respectively 
were investigated for both 24 hours incubation and 48 hours incubation in duplicate 
based on literature knowledge. Firstly, HeLa cells were passaged from their growth 
medium to 96-well plate one day before to become fresh and to form 90% confluency 
prior to transfection. Transfection mixtures of 10:1 ratio and 30:1 ratio for a single well 
of 96-well plate were prepared as shown in the Table 2.6 below and incubated at room 
temperature for 20 minutes. 
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Table 2.6. Transfection mixtures for optimization 
 
Ratio 
Component 
10 : 1 30 : 1 
DMEM Blank 20 l 20 l 
Turbofect 0.4 l 0.4 l 
pGL 4.12 (100 ng/l) 2 l (10X) 2 l (30X) 
pGL 4.74 (20 ng/l) 1 l (1X) 0.35 l (1X) 
 
 
These different ratios were examined for optimum Firefly and Renilla 
luminescence. Ratio of 10:1 were examined for both 24 hours and 48 hours as the ratio 
of 30:1 were examined seperately from each other. DLR assay was performed with 
reagents in the kit according to manufacturer’s instructions. 
 
2.11. Luminometrical Measurement of Seven Fragments    
 
Seven DNA regions that were cloned into pGL 4.12 were used as test samples in 
this assay and pGL 4.74 was used for normalization of DLR assay. Empty pGL 4.12 
was also used as negative control with pGL 4.74. In 96-well plates, three wells were 
prepared as ‘Blank’ which has only cultivated HeLa cells and standard growth medium 
without any transfected plasmids, three wells were prepared as negative control which 
includes HeLa cells co-transfected with both empty pGL 4.12 and pGL 4.74, twenty-
one wells were prepared as test samples co-transfected with seven different DNA 
regions cloned into pGL4.12 and pGL 4.74. As it can be inferred from above, all 
transfections for each DNA region were performed on the same day as triplicates. For a 
meaningful scientific conclusion, at least three independent experiments were 
performed on different days with three blanks, three negative controls and twenty-one 
independent test samples.    
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2.12.  Electrophoretic Mobility Shift Assay (EMSA)    
 
Nuclear proteins were isolated from HeLa cells using NE-PER® Nuclear and 
Cytoplasmic Extraction Reagents (Thermo Scientific, 78833). Concentration of isolated 
proteins were determined using Pierce® BCA Protein Assay Kit (Thermo Scientific, 
23225). Biotinilation of F1 fragment (187 bp), F2 fragment (358 bp), F3 fragment (591 
bp) was performed using Biotin 3' End DNA Labeling Kit (Thermo Scientific, 89818). 
EMSA was performed using LightShift® Chemiluminescent EMSA Kit (Thermo). 
Binding reactions were run on 3,5 % native-polyacrylamide gel and electroblotted to 
positively charged membrane (Pall Coorporation). Chemiluminescence was detected 
with Nucleic Acid Detection Module (Thermo Scientific, 89880). For 187 bp, 358 bp 
and 591 bp DNA regions, EMSA binding reactions were set as listed in Table 2.7. For 
supershift assay; binding reaction of c-myc antibody is shown in Table 2.8 
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Table 2.8. EMSA mixtures for 187 bp upstream region(F1) and supershift assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Component 
(l) 
F1 DNA fragment 
 
F1 DNA fragment + 
Nuclear Protein 
 
F1 DNA fragment + 
Nuclear Protein 
+ c-myc antibody 
F1 DNA fragment + 
Nuclear Protein + 
Unlabelled DNA 
dH2O 16 15 10 14 
10X Buffer 2 2 2 2 
Salmon 
Sperm 
(1g/l) 
1 1 1 1 
Unlabelled 
DNA 
- - - 1 
Nuclear 
protein 
(5 g/l) 
- 1 
1 (Nuclear protein) 
+ 
5 (c-myc) 
1 
Labelled 
DNA 
(5 pmol) 
1 1 1 
1 
(preincubation at room 
temperature for 5 min.) 
Total volume 20 20 20 20 
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CHAPTER 3 
 
RESULTS 
 
3.1.    Bioinformatic Analysis of Promoter Region for Neu4 Gene and  
Primer Design   
 
3000 bp upstream region of Neu4 gene was obtained from (The National Center 
for Biotechnology Information) and this sequence was analysed using TESS 
(Transcription Element Search System). Regulatory elements were illustrated in Figure 
3.1 as a result of TESS predictions. Primers that can amplify seven different regions 
were designed according to these regulatory elements to investigate their different 
effects. 
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Figure 3.1.  Regulatory elements in 3000 bp DNA region illustrated in different colors 
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3.2.    DNA Isolation and PCR Amplification of Seven Different 
Fragments    
 
DNA isolated from blood and its concentration measured as 70 ng/ l using 
NanoDrop ND-1000 Spectrophotometer. Seven different DNA regions were amplified 
using specific primers designed before and run on 1% agarose gel as shown in Figure 
3.2 and purified from 0,8 % agarose gel using Genejet Gel Extraction Kit (Fermentas). 
 
 
Figure 3.2. Seven different fragments amplified with PCR 
 
3.3.    TA Cloning and Confirmation with Restriction Enzyme 
Digestion    
 
All purified seven DNA fragments were cloned with TOPO TA Cloning Kit 
(Invitrogen, K4520-01) and confirmed with EcoRI digestion. Each fragment was 
screened with four colonies as examplified with F6 fragment shown in Figure 3.3. 
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Figure 3.3. Screening of F6 TA cloning 
 
3.4.    Sequence Analysis of the Cloned Fragments and BLAST Search    
 
The sequences obtained from Izmir Institute of Technology, Biotechnology and 
Bioengineering Research and Application Center were analysed using BLAST database 
and we confirmed that all the fragments matched with Neu4 gene in human genome and 
there is no Taq DNA Polymerase error. A typical BLAST output is shown in Figure 3.4. 
 
3.5.    Propagation and Confirmation of Firefly and Renilla Plasmids    
 
Confirmation of pGL4.12 with PstI and AccI digestion and confirmation of pGL 
4.74 with AlwNI and BalI digestion were shown in Figure 3.5. For pGL 4.12; PstI 
digestion produced 3057 bp and 1364 bp sequences, AccI digestion produced 2741 bp 
and 1680 bp sequences. For pGL 4.74; AlwNI digestion produced 2309 bp and 1928 bp 
sequences, BalI digestion produced 3278 bp and 959 bp sequences as confirmed on 1% 
agarose gel electrophoresis shown in Figure 3.5. 
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Figure 3.4. BLAST output of F1 sequence 
 
 
 
Figure 3.5.  Confirmation of pGL 4.12 and pGL 4.74. 1, 2 are PstI and AccI digestions 
of pGL 4.12, respectively. 3, 4 are AlwNI and BalI digestions of pGL 4.74, 
respectively. 
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3.6.    Cloning of the Fragments into pGL 4.12 Firefly Vector    
 
pGL 4.12 was seperately digested with KpnI and NheI enzymes in contrast to all 
fragments were digested from pCR2.1 TOPO vector at the same time. Fragments were 
ligated with pGL 4.12 and propagated with bacterial transformation. Cloned expression 
vectors were confirmed with double digestion with KpnI and NheI enzymes as shown in 
Figure 3.6. 
 
 
Figure 3.6.  Restriction enzyme confirmation of seven different fragments cloned into 
pGL 4.12 vector 
 
3.7.    Optimization of Dual Luciferase Reporter (DLR) Assay System  
 
DLR assay was optimized with ratios of 10:1 (pGL 4.12 : pGL 4.74) ,  
respectively and 30:1(pGL 4.12 : pGL 4.74) , respectively for both 24 hours incubation 
and 48 hours incubation times in duplicate. Luminescence obtained from samples are 
listed in Table 3.1 below. 
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Table 3.1. Optimization of DLR assay 
 
24 hours 48 hours 
Ratios Vectors 
1 2 1 2 
Firefly 3316 857 0 4547 
Blank 
Renilla 25400 592100 10850 22870 
Firefly 5565 8427 4021 4671 
10:1 
Renilla 96510 99700 268600 170600 
Firefly 11450 11700 2286 4405 
30:1 
Renilla 32920 36240 25530 27360 
 
 
Averages of blank firefly and renilla luminescence for 24 hours incubation were 
calculated seperately and the firefly average was subtracted from firefly values of 10:1 
ratio and 30:1 ratio, the renilla average was subtracted from renilla values of 10:1 ratio 
and 30:1 ratio as well. Same calculations were performed for 48 hours incubation. 
Subtracted firefly values were divided with subtracted renilla values and averages of 
these ratios were calculated as shown in Table 3.2. 
 
Table 3.2. Averages of luminescences 
 
24 hours 48 hours 
Ratio 
1 2 Average 1 2 Average 
10:1 F/R 0,048 0,085 0,067 0 0,0008 0,0004 
30:1 F/R 1,245 0,886 1,065 0 0 0 
 
 
According to optimization assays, 30:1 ratio of pGL 4.12 : pGL 4.74 incubated 
for 24 hours is the most efficient transfection condition for measuring luminescence of 
test samples. 
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3.8.    Luminometrical Measurement of Seven Fragments    
 
HeLa cells were transfected with each construct on the same day and 
additionally three independents assays (n=3) were performed different days as 
triplicates. All independent assays included blank, negative control and test samples. 
Luminescence obtained from samples are listed in Table 3.3 – 3.5 – 3.7 below. 
Averages of blank firefly and blank renilla luminescence values were subtracted from 
both negative controls and test samples as performed in optimization assay’s 
calculations. After subtraction, fold activities were calculated with the Equation 3.1 
below using renilla luminescences to normalize firefly values. Table 3.3 – 3.4, Figure 
3.7 below show fold activities for assay 1. Table 3.5 – 3.6, Figure 3.8 below show fold 
activities for assay 2 and Table 3.7 – 3.8, Figure 3.9 below show fold activities for assay 
3. 
 
 Average (Firefly/Renilla) from Sample                  
    Fold Activity =                                                                                          (3.1) 
                                         Average (Firefly/Renilla) from pGL4-Basic 
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3.8.1.  Assay 1    
 
Table 3.3. Measured luminescence values (n=1) 
 
n=1 
Light 
Units 
Blank 
Negative 
Control 
F1 F2 F3 F4 F5 F6 F7 
Firefly 342.4 3792 32430 60200 69610 78030 34480 57380 39900 
1 
Renilla 2343 27790 63990 68380 73960 79550 76840 87020 71950 
Firefly 0 7147 32440 95310 85210 83130 38660 64310 62830 
2 
Renilla 2370 57540 72260 94990 80200 100200 88170 103100 91300 
Firefly 0 7933 58520 81540 95670 98250 45220 62750 63380 
3 
Renilla 2362 60540 118600 74080 89930 111500 112800 115500 65440 
 
 
Table 3.4. Calculated fold activities of assay (n=1) 
 
n=1 
Light 
Units 
Negative 
Control 
F1 F2 F3 F4 F5 F6 F7 
1 F/R 0,1356 0,5206 0,9066 0,9674 1,0064 0,4583 0,6737 0,5684 
2 F/R 1.1233 0,4591 1,0252 1,0902 0,8461 0,4465 0,6349 0,7025 
3 F/R 0,1304 0,5004 1,1321 1,0885 0,8970 0,4063 0,5515 0,9993 
Average F/R 0,4631 0,4933 1,0213 1,0487 0,9165 0,4370 0,6200 0,7567 
 Fold Activity 1,0652 2,2053 2,2645 1,9790 0,9436 1,3388 1,3720 
 
 
 
Figure 3.7. Graphic representing the fold activities of assay (n=1) 
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3.8.2.  Assay 2    
 
Table 3.5 Measured luminescence values (n=2) 
 
n=2 
Light 
Units 
Blank 
Negative 
Control 
F1 F2 F3 F4 F5 F6 F7 
Firefly 2496 9631 31770 26030 22560 32630 17200 30430 3645 
1 
Renilla 4674 102200 77090 72450 44810 107900 123300 160100 9478 
Firefly 1930 7289 28830 38400 46390 33830 14870 33900 11000 
2 
Renilla 3618 77830 63290 97440 85330 100300 84200 147700 40740 
Firefly 1912 10190 27220 63000 25970 15500 27950 53380 3144 
3 
Renilla 3464 86670 45500 106900 41810 45120 102300 147000 11300 
 
 
Table 3.6 Calculated fold activities of assay (n=2) 
 
n=2 
Light 
Units 
Negative 
Control 
F1 F2 F3 F4 F5 F6 F7 
1 F/R 0,0764 0,4053 0,3489 0,5000 0,2934 0,1263 0,1813 0,2756 
2 F/R 0,0700 0,4500 0,3880 0,5438 0,3290 0,1589 0,2210 0,2413 
3 F/R 0,0976 0,6038 0,5912 0,6296 0,3249 0,2626 0,3583 0,1397 
Average F/R 0,0813 0,4863 0,4427 0,5578 0,3157 0,1826 0,2435 0,2188 
 Fold Activity 5,9815 5,4452 6,8610 3,8831 2,2460 3,1180 2,6912 
 
 
 
Figure 3.8. Graphic representing the fold activities of assay (n=2) 
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3.8.3.  Assay 3    
 
Table 3.7. Measured luminescence values (n=3) 
 
n=3 
Light 
Units 
Blank 
Negative 
Control 
F1 F2 F3 F4 F5 F6 F7 
Firefly 6291 20510 71350 89290 94840 64890 30830 53550 30040 1 
Renilla 14270 298600 160900 375700 260600 189500 292600 323000 293000 
Firefly 4741 16190 55170 117600 99490 72820 35100 73100 53290 2 
Renilla 12190 281400 138700 402000 280600 214100 296400 333300 343200 
Firefly 4114 20110 63960 117400 75520 88060 33780 98770 58720 3 
Renilla 9630 242800 88820 239100 145600 166800 200000 290300 304300 
 
 
Table 3.8. Calculated fold activities of assay (n=3) 
 
n=2 
Light 
Units 
Negative 
Control 
F1 F2 F3 F4 F5 F6 F7 
1 F/R 0,0539 0,4453 0,2316 0,3612 0,3371 0,0918 0,1559 0,0889 
2 F/R 0,0413 0,3956 0,2886 0,3516 0,3353 0,1056 0,2118 0,1456 
3 F/R 0,0652 0,7671 0,4947 0,5276 0,5363 0,1528 0,3368 0,1836 
Average F/R 0,0534 0,5360 0,3383 0,4134 0,4029 0,1167 0,2368 0,1393 
 Fold Activity 10,0374 6,3352 7,7415 7,5449 2,1853 4,4344 2,6086 
 
 
 
Figure 3.9 Graphic representing the fold activities of assay (n=3) 
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3.8.4.  Fold Activities of All Measurements 
    
All calculated fold changes were averaged together and standard deviations of 
these changes were calculated in MS Excel as shown in Table 3.9 and Figure 3.10. 
 
Table 3.9. Average of all calculated assays and standard deviations 
 
n 
Light 
Units 
Negative 
Control 
F1 F2 F3 F4 F5 F6 F7 
n=1 F/R 0,4631 1,0652 2,2053 2,2645 1,9790 0,9436 1,3388 1,3720 
n=2 F/R 0,0813 5,9815 5,4452 6,8610 3,8831 2,2460 3,1180 2,6912 
n=3 F/R 0,0534 10,0374 6,3352 7,7415 7,5449 2,1853 4,4344 2,6086 
Average F/R 0,1992 
 
5,6922 
 
4,6601 5,6218 4,4673 1,7898 2,9489 2,2210 
Average F/R 
Standard deviation 
0,2289 4,4929 2,1735 2,9411 2,8288 0,7350 1,5535 0.7389 
 Average F/R 
Fold Activity 
19,6282 9,4954 12,8488 12,3582 3,2110 6,7868 3,2280 
 
 
 
Figure 3.10. Graphic representing average of all assays with standard deviations 
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3.9.    Electrophoretic Mobility Shift Assay (EMSA)    
 
EMSA images representing free biotinilated DNA and DNA:protein complex 
(Shift) formation with 187 bp, 358 bp and 591 bp upstream regions are shown in Figure 
3.11 – 3.12- 3.13 below. 
 
 
 
Figure 3.11.  A, schematic presentation of a typical EMSA components. B,    Image 
showing EMSA result of 187 bp upstream region (F1). 1, biotinilated 
free DNA; 2, DNA:protein complex (Shift), 3, competition assay proving 
specific binding of transcription factors to F1 fragment releasing 
biotinilated DNA free.  
 
 
 
 
 
45 
 
 
Figure 3.12.  A, schematic presentation of a typical EMSA components. B, Image 
showing EMSA result of 358 bp upstream region (F2). 1, biotinilated 
free DNA; 2, DNA:protein complex (Shift), 3, competition assay 
providing specific binding of transcription factors to F2 fragment 
releasing biotinilated DNA free. 
 
 
Figure 3.13.  A, schematic presentation of a typical EMSA components. B, Image 
showing EMSA result of 591 bp upstream region (F3). 1, biotinilated 
free DNA; 2, DNA:protein complex (Shift), 3, competition assay proving 
specific binding of transcription factors to F3 fragment releasing 
biotinilated DNA free. 
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3.10.    Supershift Assay with c-myc Antibody 
 
EMSA image representing DNA:protein complex (Shift) formation and 
DNA:Protein:c-myc complex formation (Supershift) with 187 bp upstream region are 
shown in Figure 3.14. 
 
 
 
Figure 3.14.  A, schematic presentation of a typical EMSA components. B, Image 
showing supershift result of 187 bp upstream region (F1) with c-myc 
antibody. 1, biotinilated free DNA; 2, DNA:protein complex (Shift),  3, 
supershift formation with c-myc antibody; 4, competition assay proving 
specific binding of transcription factors to F1 fragment releasing 
biotinilated DNA free. 
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CHAPTER 4 
 
DISCUSSION 
 
Neuraminidases (sialidases) show a wide distribution from viruses to vertebrates 
in nature. They remove sialic acid residues from glycoconjugates (Saito and Yu 1995). 
In human, four types of neuraminidases have been identified and cloned (Bonten 2000). 
Lysosomal/mitochondrial neuraminidase 4 (Neu4) is one of them and it has activity 
against sialylated glycoproteins, oligosaccharides, glycolipids in vitro (Seyrantepe et al. 
2004; Monti et al. 2004). Neu4 deficient mice showed an increase in GD1a ganglioside 
levels and a decrease in GM1 ganglioside levels in brain indicating activity of Neu4 
against gangliosides.  In addition lung and spleen of Neu4 deficient mice revealed 
vacuolization and lysosomal storage (Seyrantepe et al. 2008).   
In this study, our aim is to perform molecular analysis of the 5’ upstream 
regulatory region of human Neu4 gene. Although biochemical properties of human 
sialidase Neu4 enzyme was reported, Neu4 promoter region has not been studied yet. 
The data we obtained in this study provided an important clue about the molecular 
mechanism regulating human Neu4 gene expression.  Here, we focused on 3000 bp 
upstream region of human Neu4 as a candidate promoter region. Bioinformatic analysis 
accomplished using TESS (Transcription Element Search System) tool revealed several 
putative transcription factor binding sites like c-myc, SP-1, YY1, AP-1 etc. in that 
region. TATA Box Hunting research tool using Genomatix revealed the absence of 
TATA box. In addition, the analysis of GC boxes using MBCF (Molecular Biology 
Core Facilities). Oligo Calculator revealed that 3000 bp upstream of human Neu4 has 
61% GC content indicating potential transcription binding sites. We amplified and 
cloned seven different DNA fragments and sequenced them to confirm Taq Polymerase 
errors. Dual luciferase reporter system was used due to its experimental accuracy and 
high sensitivity as it can report femtograms of luciferase. Amplified DNA fragments 
were subcloned into pGL 4.12 vector. Optimization assays showed that parameters 
including the ratio of 30:1 (pGL 4.12:pGL 4.74, respectively) and 24 hours incubation 
time are optimum for Dual Luciferase Reporter System. All reporter assays were 
repeated three times. The data obtained using Dual Luciferase Reporter System showed 
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that 187 base pair upstream region (F1 fragment) has minimal transcriptional regulatory 
activity for human Neu4 gene with its highest luminescence among the others. We 
found that fold activity of luminescence gradually decreased between 187 bp and 1187 
bp region. On the other hand, 358 upstream region showed a significant decrease in fold 
activities due to potential elements probably responsible for down-regulation of Neu4 
gene. In addition, significantly decreased fold activities of luminescence were detected 
in 1592 bp, 2364 bp, 3011 bp upstream regions due to the effect of potential silencer 
elements. For instance, 187 bp region (F1 fragment) that has dominant promoter activity 
showed six times higher fold activity than 1592 bp region (F5 fragment). EMSA 
revealed that 187 bp, 358 bp, 591 bp upstream regions recruits some transcription 
factors as seen in ‘Shift’ formation with incubation of biotinilated DNA with nuclear 
proteins. Addition of unlabelled 187 bp, 358 bp, 591 bp regions into binding reactions 
proved the specificity of binding of transcription factors to candidate promoter region. 
EMSA also confirmed another supporting evidence for regulatory  role of 187 bp 
upstream region (F1 fragment) as we determined formation of ‘specific shift’ at protein 
level besides its highest luminescence fold activity.  In particular, we showed the 
binding of c-myc to our minimal promoter region by supershift assay. The highest 
luminescence obtained from 187 bp upstream region (F1 fragment) of human Neu4 
gene may be a result of predicted transcription factor binding sites for c-myc which is 
also responsible for transcription regulation of many genes involved cellular events such 
as cell proliferation and differentiation.  
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CHAPTER 5 
 
CONCLUSION 
 
In this study we report the molecular characterization of promoter region of 
human Neu4 gene for the first time. Our lucifarese reporter assays demostrated 187 bp 
TATA-less promoter is required for minimal activity. Upstream regions from 187 bp 
showed a decrease in activity. Our EMSA results supported the specific binding of 
transcription factors such as c-myc at protein level to the same region. 
In the future, the data we obtained can be used for discovering small molecules 
which may control human Neu4 gene expression. Selective high expression or silencing 
of Neu4 gene might be achieved using drugs or small molecules. High expression of 
Neu4 gene and increased level of Neu4 neuraminidase in tissues can clear accumulated 
GM2 ganglioside in lysosomes of Tay-Sachs patients due to beta-hexosaminidase A 
deficiency.  
It has been shown that Neu4 is downregulated in human colon cancer cells and 
overexpression of Neu4 in cultured cells accelerates apoptosis and decreases 
invasiveness and motility. Research to study the upregulation of human Neu4 gene 
expression by selective binding of c-myc protein into the promoter region might be 
important to treat human colon cancer. 
  In addition, the importance of  up and/or  down regulation of Neu4 gene 
expression  in degradation of biomolecules, cellular communication, cell growth and 
differentiation and cell death can be enlightened.     
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